» Articles » PMID: 27920610

Volumetric Image-guided Highly Conformal Radiotherapy of the Prostate Bed: Toxicity Analysis

Overview
Specialty Oncology
Date 2016 Dec 7
PMID 27920610
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: To evaluate toxicity of high conformal image-guided radiotherapy of the prostate bed.

Background: Radiotherapy of the prostate bed has a pivotal role in the post-operative and salvage settings, but few clinical data are available on the use of daily image guidance in combination with highly conformal techniques, and data on long-term results are lacking.

Materials And Methods: We analyzed 118 patients irradiated on the prostate bed using conformal plans processed with a micro-multileaf collimator, and daily checking treatment set-up with a cone-beam CT system. Correlation between toxicity and clinical-dosimetric parameters was assessed by the Cox regression model and log-rank test. Survival analyses were performed with the Kaplan-Meier method.

Results: Median follow-up was 54.08 months. Late grade ≥2 gastro-intestinal (GI) and genito-urinary (GU) toxicity were 3.4% and 4.2%, respectively. Actuarial 4-year late grade ≥2 GI and GU toxicities were 4% and 6%, respectively. Four-year relapse-free survival was 87%. At log-rank test, acute grade ≥2 GI toxicity is associated with the use of antihypertensives ( = 0.03), and there is a trend toward significance between the use of anticoagulants and late grade ≥2 GI toxicity ( = 0.07). At Cox analysis, acute grade ≥2 GU toxicity is correlated with the percentage of bladder volume receiving more than 65 Gy ( = 0.02, HR 1.87 CI 1.25-2.8), and the maximal dose to the rectum is correlated to the development of late grade ≥2 GI toxicity ( = 0.03, HR 2.75 CI 1.10-6.9).

Conclusions: Conformal volumetric image-guided radiotherapy of the prostate bed leads to low toxicity rates.

Citing Articles

Tomotherapy-based moderate hypofractionation for localized prostate cancer: a mono-institutional analysis.

Tenti M, Ingrosso G, Bini V, Mariucci C, Saldi S, Ali E Rep Pract Oncol Radiother. 2022; 27(1):142-151.

PMID: 35402018 PMC: 8989459. DOI: 10.5603/RPOR.a2022.0012.


Toxicity reduction required for MRI-guided radiotherapy to be cost-effective in the treatment of localized prostate cancer.

Schumacher L, Dal Pra A, Hoffe S, Mellon E Br J Radiol. 2020; 93(1114):20200028.

PMID: 32783629 PMC: 7548359. DOI: 10.1259/bjr.20200028.


Salvage radiation therapy in prostate cancer: relationship between rectal dose and long-term, self-reported rectal bleeding.

Braide K, Kindblom J, Lindencrona U, Hugosson J, Pettersson N Clin Transl Oncol. 2020; 23(2):397-404.

PMID: 32621207 PMC: 7854429. DOI: 10.1007/s12094-020-02433-4.

References
1.
Takeda K, Ogawa Y, Ariga H, Koto M, Sakayauchi T, Fujimoto K . Clinical correlations between treatment with anticoagulants/antiaggregants and late rectal toxicity after radiotherapy for prostate cancer. Anticancer Res. 2009; 29(5):1831-4. View

2.
Nath S, Sandhu A, Rose B, Simpson D, Nobiensky P, Wang J . Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2009; 78(2):435-41. DOI: 10.1016/j.ijrobp.2009.08.023. View

3.
De Meerleer G, Fonteyne V, Meersschout S, Van den Broecke C, Villeirs G, Lumen N . Salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy. Radiother Oncol. 2008; 89(2):205-13. DOI: 10.1016/j.radonc.2008.07.027. View

4.
Daly T, Hickey B, Lehman M, Francis D, See A . Adjuvant radiotherapy following radical prostatectomy for prostate cancer. Cochrane Database Syst Rev. 2011; (12):CD007234. DOI: 10.1002/14651858.CD007234.pub2. View

5.
Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A . Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol. 2014; 66(2):243-50. DOI: 10.1016/j.eururo.2014.03.011. View